SCHEDULE: Nantahala Capital Discloses 9.99% Stake in Abeona

Nantahala Capital Management, along with Wilmot B. Harkey and Daniel Mack, reported a 9.99% beneficial ownership stake in Abeona Therapeutics Inc.

Summary

• Nantahala Capital Management, LLC, Wilmot B. Harkey, and Daniel Mack (collectively, the "Reporting Persons") beneficially own 5,184,662 shares of Abeona Therapeutics Inc. common stock.
• This ownership represents 9.99% of the total class of securities outstanding.
• The calculation is based on 51,278,539 shares outstanding as reported by the issuer in its August 14, 2025 10-Q filing for June 30, 2025.
• The beneficially owned shares include 619,997 shares that can be acquired within sixty days through the exercise of warrants.
• The Reporting Persons hold shared voting and shared dispositive power over all 5,184,662 shares.
• The securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 7

Explanation: The disclosure of a significant, passive stake by a reputable investment firm like Nantahala Capital Management is generally viewed positively, indicating institutional confidence in the company without suggesting immediate activist intentions.

Positives

• A significant stake (9.99%) by an institutional investor like Nantahala Capital Management can signal confidence in Abeona Therapeutics' future prospects.
• The investment is stated to be in the ordinary course of business, suggesting a passive, long-term investment strategy rather than an activist one.

Negatives

• No specific negative information regarding Abeona Therapeutics Inc. is disclosed in this ownership filing.

Risks

• The value of the investment is subject to market fluctuations inherent in publicly traded securities.
• The Reporting Persons' ability to influence the company's direction is limited as they disclaim intent to change or influence control.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding Abeona Therapeutics Inc.'s future financial performance or strategic direction.

Industry Context

This filing indicates a significant passive investment by a hedge fund in a biotechnology company. Such investments are common as institutional investors seek to gain exposure to specific sectors or companies they believe have strong growth potential. For Abeona Therapeutics, a biotech firm, attracting institutional investment can be a positive signal of market interest in its pipeline or technology.

Related Party Transactions

• NANTAHALA CAPITAL PARTNERS LIMITED PARTNERSHIP, a fund advised by Nantahala Capital Management, has the right to receive or direct the receipt of dividends or proceeds from the sale of more than five percent of the outstanding common stock beneficially owned by Nantahala.

Stakeholder Impact

• Shareholders: The presence of a significant institutional investor may provide a degree of stability and confidence in the stock.
• Management: The filing indicates a passive investment, suggesting no immediate pressure for management changes or strategic shifts from this investor.

Key Dates

Recommendation

The filing indicates a significant institutional investment, which can be a positive signal of confidence. However, as a Schedule 13G, it's a passive ownership disclosure and does not provide new operational or financial performance data for Abeona Therapeutics Inc. Without additional fundamental information, a 'hold' recommendation is appropriate, acknowledging the positive signal of institutional interest while awaiting further company-specific news or financial results to justify a stronger stance.

Keywords

Abeona Therapeutics, Nantahala Capital Management, Wilmot B. Harkey, Daniel Mack, Beneficial Ownership, Schedule 13G, Common Stock, Investment Adviser, Biotechnology, Pharmaceuticals